AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31455566 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback Guide intervention
Number of subjects: 29
Study 31455566 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 29
Study 30563932 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg daily for 3 days, then twice daily for 1 to 5 weeks)
Number of subjects: 88
Study 30563932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 30563932 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 88
Study 27654012 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical hyaluronic acid (HA) and chondroitin sulfate (CS)
Number of subjects: 110
Study 27654012 — intervention group
Group type: COMPARATOR
Intervention: Dimethyl sulfoxide (DMSO)
Number of subjects: 110
Study 25945555 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxylator-aided laryngeal tube ventilation (OLTV)
Number of subjects: 17
Study 25945555 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth-to-mouth ventilation (MMV)
Number of subjects: 17
Study 25945555 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxylator-aided mask ventilation (OMV)
Number of subjects: 17
Study 25945555 — intervention group
Group type: EXPERIMENTAL
Intervention: No ventilation (NV)
Number of subjects: 17
Study 24063678 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardio Zip shoe
Number of subjects: 36
Study 24063678 — intervention group
Group type: EXPERIMENTAL
Intervention: All shoes at 8-weeks
Number of subjects: 36
Study 24063678 — intervention group
Group type: COMPARATOR
Intervention: Other three shoes
Number of subjects: 36
Study 21318314 — intervention group
Group type: EXPERIMENTAL
Intervention: Hopping at 1.5 Hz
Number of subjects: 14
Study 21318314 — intervention group
Group type: EXPERIMENTAL
Intervention: Hopping at 2.2 Hz
Number of subjects: 14
Study 21318314 — intervention group
Group type: EXPERIMENTAL
Intervention: Hopping at 3.0 Hz
Number of subjects: 14
Study 19479614 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved field radiotherapy (RT) after induction chemotherapy (CT)
Number of subjects: 54
Study 19479614 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CT) alone
Number of subjects: 54
Study 18246732 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy
Number of subjects: 150
Study 18246732 — intervention group
Group type: EXPERIMENTAL
Intervention: Band ligation
Number of subjects: 150
Study 18246732 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 150
Study 14684415 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion
Number of subjects: 100
Study 14684415 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study 11485506 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron hydrochloride 1 mg twice daily for 12 weeks
Number of subjects: 626
Study 11485506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 626
Study 9740096 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance (MR) bolus tracking
Number of subjects: 6
Study 9740096 — intervention group
Group type: COMPARATOR
Intervention: [(15)O]H2O positron emission tomography (PET)
Number of subjects: 6
Study 8035989 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet
Number of subjects: 0
Study 8035989 — intervention group
Group type: COMPARATOR
Intervention: Ganciclovir
Number of subjects: 0
Study 2692178 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral salbutamol 4 mg t.d.s.
Number of subjects: 90
Study 2692178 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous salbutamol infused until maternal heart rate rose above 100 bpm for 30 mins
Number of subjects: 90
Study 2692178 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tocolysis)
Number of subjects: 90
Study 1146460 — intervention group
Group type: EXPERIMENTAL
Intervention: Various therapeutic protocols
Number of subjects: 0
Study 27889661 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening with PSA threshold of 3 ng/ml
Number of subjects: 0
Study 27889661 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening with PSA threshold of 4 ng/ml
Number of subjects: 0
Study 27889661 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening interval of two years
Number of subjects: 0
Study 27889661 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening interval of four years
Number of subjects: 0
Study 27889661 — intervention group
Group type: COMPARATOR
Intervention: Control arm (Finland)
Number of subjects: 0
Study 26272447 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy with lavender oil (2 consecutive cycles of effleurage massage)
Number of subjects: 102
Study 26272447 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercises (8 weeks)
Number of subjects: 102
Study 26272447 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 102
Study 24156091 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement taken each dialysis session (drink or pudding style)
Number of subjects: 30
Study 24156091 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 30
Study 24156091 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement
Number of subjects: 30
Study 22205554 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT/LCT fat infusion
Number of subjects: 40
Study 22205554 — intervention group
Group type: COMPARATOR
Intervention: Fish oil‐based (ω‐3) fat infusion
Number of subjects: 40
Study 22205554 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis group 1 (S1)
Number of subjects: 40
Study 22205554 — intervention group
Group type: COMPARATOR
Intervention: Sepsis group 2 (S2)
Number of subjects: 40
Study 19078948 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 595
Study 16918949 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment (1.3, 2.0 and 2.7 mg/m2/day)
Number of subjects: 65
Study 16918949 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment (2.7 mg/m2/day)
Number of subjects: 65
Study 16918949 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 65
Study 12950901 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg twice a day for 2 days (days 1 and 2)
Number of subjects: 45
Study 12950901 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg twice a day for 8 days (days 1 and 8)
Number of subjects: 45
Study 12950901 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole 200 mg single dose (day 1)
Number of subjects: 45
Study 10872186 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) treatment
Number of subjects: 10
Study 10872186 — intervention group
Group type: COMPARATOR
Intervention: Control group (children without rhGH treatment)
Number of subjects: 10
Study 9166391 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipriflavone (200 mg t.i.d)
Number of subjects: 255
Study 9166391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 9166391 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipriflavone
Number of subjects: 255
Study 1545589 — intervention group
Group type: EXPERIMENTAL
Intervention: Eder-Puestow dilators
Number of subjects: 123
Study 1545589 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon dilators
Number of subjects: 123
Study 4074623 — intervention group
Group type: EXPERIMENTAL
Intervention: +sotalol (0.125 mg kg‐1 to 2.0 mg kg‐1)
Number of subjects: 6
Study 4074623 — intervention group
Group type: COMPARATOR
Intervention: (+/‐)‐sotalol
Number of subjects: 6
Study 31352900 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark-blood LGE
Number of subjects: 300
Study 31352900 — intervention group
Group type: COMPARATOR
Intervention: Bright-blood LGE
Number of subjects: 300
Study 29718811 — intervention group
Group type: EXPERIMENTAL
Intervention: Total offloading foot brace
Number of subjects: 17
Study 29718811 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (control)
Number of subjects: 17
Study 26519439 — intervention group
Group type: EXPERIMENTAL
Intervention: MMFS-01
Number of subjects: 44
Study 26519439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 23865441 — intervention group
Group type: EXPERIMENTAL
Intervention: LOS + HCTZ (50 mg/day losartan + 12.5 mg/day hydrochlorothiazide)
Number of subjects: 59
Study 23865441 — intervention group
Group type: EXPERIMENTAL
Intervention: TEL + HCTZ (40 mg/day telmisartan + 12.5 mg/day hydrochlorothiazide)
Number of subjects: 59
Study 23514683 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin modified glass ionomer cement
Number of subjects: 150
Study 23514683 — intervention group
Group type: EXPERIMENTAL
Intervention: Compomer
Number of subjects: 150
Study 23514683 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin
Number of subjects: 150
Study 23514683 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual curing resin cement
Number of subjects: 150
Study 23514683 — intervention group
Group type: COMPARATOR
Intervention: Control group (intact tooth)
Number of subjects: 150
Study 20093961 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity (65% 1 repetition maximum [1RM])
Number of subjects: 17
Study 20093961 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity (85% 1RM)
Number of subjects: 17
Study 20093961 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple set protocols
Number of subjects: 17
Study 20093961 — intervention group
Group type: COMPARATOR
Intervention: Single set protocols
Number of subjects: 17
Study 20093961 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity, multiple set bout
Number of subjects: 17
Study 18713908 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Support Ventilation (ASV)
Number of subjects: 346
Study 18713908 — intervention group
Group type: COMPARATOR
Intervention: Pressure-controlled/pressure-support MV
Number of subjects: 346
Study 11386625 — intervention group
Group type: EXPERIMENTAL
Intervention: Equity-focused screening test offered to 100% of the Medicaid population
Number of subjects: 0
Study 11386625 — intervention group
Group type: COMPARATOR
Intervention: Equity-focused screening test offered to half of the Medicaid population
Number of subjects: 0
Study 11386625 — intervention group
Group type: EXPERIMENTAL
Intervention: Order of scenarios presented to subjects
Number of subjects: 0
Study 11386625 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad framing of population for screening
Number of subjects: 0
Study 11386625 — intervention group
Group type: COMPARATOR
Intervention: Narrow framing of population for screening
Number of subjects: 0
Study 9473250 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA‐identical sibling transplants
Number of subjects: 744
Study 9473250 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea or interferon
Number of subjects: 744
Study 7846193 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (mean dose 75 mg daily) plus mianserin (mean dose 25 mg daily)
Number of subjects: 20
Study 7846193 — intervention group
Group type: COMPARATOR
Intervention: Desipramine (mean dose 66 mg daily) plus mianserin (mean dose 27 mg daily)
Number of subjects: 20
Study 7846193 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of side-effects using the UKU scale
Number of subjects: 20
Study 7846193 — intervention group
Group type: EXPERIMENTAL
Intervention: Melancholia Scale (MES)
Number of subjects: 20
Study 7846193 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamilton Depression Scale (HAMD)
Number of subjects: 20
Study 3362395 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior resection plus intracolonic by-pass (ARIB)
Number of subjects: 19
Study 3362395 — intervention group
Group type: COMPARATOR
Intervention: Anterior resection (AR)
Number of subjects: 19
Study 3362395 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior resection (ARIB)
Number of subjects: 19
Study 31172644 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (200 mg oral administration)
Number of subjects: 100
Study 31172644 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone (intravaginal instillation)
Number of subjects: 100
Study 29103416 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlai capsules 100 mg
Number of subjects: 20
Study 29103416 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlai capsules 200 mg
Number of subjects: 20
Study 29103416 — intervention group
Group type: COMPARATOR
Intervention: Loratadine 10 mg
Number of subjects: 20
Study 25882986 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib plus weekly paclitaxel (800 mg daily + 80 mg/m² weekly)
Number of subjects: 74
Study 25882986 — intervention group
Group type: COMPARATOR
Intervention: Weekly paclitaxel alone (80 mg/m² weekly)
Number of subjects: 74
Study 25882986 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib plus weekly paclitaxel
Number of subjects: 74
Study 24306019 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional remediation program
Number of subjects: 0
Study 24306019 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitness for Life program (pedometer-based program with individual counseling and follow-up calls)
Number of subjects: 0
Study 24306019 — intervention group
Group type: COMPARATOR
Intervention: Fitness for Life program
Number of subjects: 0
Study 22813409 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol (60,000 units/week) and calcium carbonate (1g/day) along with anti-tubercular treatment (ATT)
Number of subjects: 45
Study 22813409 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin D supplementation)
Number of subjects: 45
Study 19401624 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Relaxation (FR)
Number of subjects: 64
Study 19401624 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Imagery (GI)
Number of subjects: 64
Study 19401624 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FR and GI (FR/GI)
Number of subjects: 64
Study 19401624 — intervention group
Group type: COMPARATOR
Intervention: Placebo Relaxation Technique (Control Intervention)
Number of subjects: 64
Study 16395307 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 25 mg pretreatment with lower subperceptual ketamine dose (0.081 mg/kg bolus, 0.4 mg/kg/h infusion)
Number of subjects: 55
Study 16395307 — intervention group
Group type: COMPARATOR
Intervention: Higher perception-altering ketamine dose (0.23 mg/kg bolus, 0.58 mg/kg infusion)
Number of subjects: 55
Study 16395307 — intervention group
Group type: COMPARATOR
Intervention: Lower subperceptual ketamine dose
Number of subjects: 55
Study 16395307 — intervention group
Group type: COMPARATOR
Intervention: Higher ketamine dose
Number of subjects: 55
Study 16395307 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone
Number of subjects: 55
Study 15005907 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral psoriasis symptom management programme (PSMP)
Number of subjects: 40
Study 15005907 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmacological care
Number of subjects: 40
Study 10890543 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic approach
Number of subjects: 50
Study 10890543 — intervention group
Group type: COMPARATOR
Intervention: Open approach
Number of subjects: 50
Study 9059198 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (group A)
Number of subjects: 28
Study 9059198 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (group F)
Number of subjects: 28
Study 9059198 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil (group S)
Number of subjects: 28
Study 8370859 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment
Number of subjects: 0
Study 8370859 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment
Number of subjects: 0
Study 8370859 — intervention group
Group type: COMPARATOR
Intervention: Attention placebo (nonspecific self-monitoring)
Number of subjects: 0
Study 31629207 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive nurse-led discharge intervention
Number of subjects: 200
Study 31629207 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard discharge process)
Number of subjects: 200
Study 27992944 — intervention group
Group type: EXPERIMENTAL
Intervention: Google Glass intervention used by otolaryngology residents
Number of subjects: 95
Study 26703286 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal add-on IOL (Diff-sPB) in the sulcus
Number of subjects: 26
Study 26703286 — intervention group
Group type: COMPARATOR
Intervention: Conventional multifocal IOL (Diffractiva-s) in the capsular bag
Number of subjects: 26
Study 23439461 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (n = 9)
Number of subjects: 56
Study 23439461 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermia (n = 10)
Number of subjects: 56
Study 23439461 — intervention group
Group type: COMPARATOR
Intervention: Control (diagnostic lumbar puncture, n = 5)
Number of subjects: 56
Study 20431933 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient HIV counseling and testing (HCT)
Number of subjects: 500
Study 20431933 — intervention group
Group type: COMPARATOR
Intervention: Outpatient HIV counseling and testing (HCT) 1 week post-discharge
Number of subjects: 500
Study 19222770 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative local anesthetic mixture (10 mL 2% lidocaine added to 10 mL 0.5% bupivacaine)
Number of subjects: 80
Study 19222770 — intervention group
Group type: COMPARATOR
Intervention: Preoperative saline and postoperative local anesthetic mixture (10 mL 2% lidocaine added to 10 mL 0.5% bupivacaine)
Number of subjects: 80
Study 19222770 — intervention group
Group type: COMPARATOR
Intervention: Preoperative local anesthetic mixture and postoperative saline
Number of subjects: 80
Study 19222770 — intervention group
Group type: COMPARATOR
Intervention: Preoperative and postoperative 0.9% saline
Number of subjects: 80
Study 16508385 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 days before surgery and on the morning of surgery
Number of subjects: 30
Study 16508385 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo for 4 days before surgery and oral rofecoxib 50 mg on the morning of surgery
Number of subjects: 30
Study 16508385 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rofecoxib 50 mg for 4 days before surgery and the morning of surgery
Number of subjects: 30
Study 15266820 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 999
Study 15266820 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 999
Study 11524352 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine (15 mL, 75 mg)
Number of subjects: 117
Study 11524352 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine with 1:400,000 epinephrine
Number of subjects: 117
Study 11524352 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine with 1:200,000 epinephrine
Number of subjects: 117
Study 9236446 — intervention group
Group type: EXPERIMENTAL
Intervention: Sidestream smoke exposure
Number of subjects: 17
Study 9236446 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (air) inhalation
Number of subjects: 17
Study 8103703 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (15 mg single dose)
Number of subjects: 10
Study 8103703 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (15 mg twice daily for 1 week)
Number of subjects: 10
Study 8103703 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after single dose PAF challenge)
Number of subjects: 10
Study 8103703 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after 1 week treatment)
Number of subjects: 10
Study 3092699 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15‐0.2 mg/kg nalbuphine
Number of subjects: 60
Study 3092699 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75‐1.0 mg/kg tramadol
Number of subjects: 60
Study 30350758 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Anterior (DA) approach
Number of subjects: 100
Study 30350758 — intervention group
Group type: COMPARATOR
Intervention: Conventional Direct Lateral (DL) approach
Number of subjects: 100
Study 27545351 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day interdialytic interval
Number of subjects: 41
Study 24886353 — intervention group
Group type: EXPERIMENTAL
Intervention: ThinkingFit intervention (complex multimodal activity programme)
Number of subjects: 67
Study 22246982 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mJ double pulse CO(2) laser
Number of subjects: 12
Study 22246982 — intervention group
Group type: COMPARATOR
Intervention: 30 mJ single pulse CO(2) laser
Number of subjects: 12
Study 20299995 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound out-of-plane approach
Number of subjects: 120
Study 20299995 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound in-plane approach
Number of subjects: 120
Study 20299995 — intervention group
Group type: COMPARATOR
Intervention: Neurostimulation
Number of subjects: 120
Study 18420265 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-push-out test (Mpo)
Number of subjects: 30
Study 18420265 — intervention group
Group type: EXPERIMENTAL
Intervention: Hourglass-shaped microtensile test (Mh)
Number of subjects: 30
Study 18420265 — intervention group
Group type: COMPARATOR
Intervention: Push-out test
Number of subjects: 30
Study 16896732 — intervention group
Group type: EXPERIMENTAL
Intervention: E40% (40% of 1 RM)
Number of subjects: 17
Study 16896732 — intervention group
Group type: EXPERIMENTAL
Intervention: E80% (80% of 1 RM)
Number of subjects: 17
Study 16896732 — intervention group
Group type: COMPARATOR
Intervention: C (40 min of rest)
Number of subjects: 17
Study 12508294 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulnar segmental nerve conduction studies (SgNCS) at 2‐cm intervals
Number of subjects: 21
Study 12508294 — intervention group
Group type: COMPARATOR
Intervention: Routine ulnar motor and sensory studies
Number of subjects: 21
Study 10775708 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic prospective-memory task with perceptual on-going task; Session 1 performance was particularly bad for Korsakoff patients.
Number of subjects: 0
Study 10775708 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic prospective-memory task with semantic on-going task;
Number of subjects: 0